News
-
-
PRESS RELEASE
Redx Reports Encouraging Zamaporvint (RXC004) Phase 2 Combination Data in MSS mCRC at ESMO GI Congress Supporting Genetic Selection Hypothesis in Hard-to-Treat GI Cancers
Redx Pharma presents positive Phase 2 data on Zamaporvint (RXC004) at ESMO GI Congress, supporting genetic selection hypothesis in hard-to-treat GI cancers. Potential new treatment option for MSS mCRC patients -
-
-
-
-
-
-
-